Pembrolizumab for metastatic castration-resistant prostate cancer: trials and tribulations.
Alexander K TsaiSana KagalwallaJenna LangerThuy Le-KumarVikas Le-KumarEmmanuel S AntonarakisPublished in: Expert opinion on biological therapy (2024)
Pembrolizumab has not benefitted unselected metastatic prostate cancer patients when combined with chemotherapy, next-generation hormonal agents (NHA), or poly(ADP-ribose) polymerase inhibitors (PARPi). PD-L1 positivity does not predict the response to pembrolizumab in this disease. A small number of responding patients can likely be explained by rare genetic and molecular defects, and more innovative combination strategies are needed to improve outcomes in prostate cancer patients who are not sensitive to pembrolizumab. Emphasis should be placed on developing additional or alternative immuno-oncology approaches beyond classical immune checkpoint inhibition.
Keyphrases
- prostate cancer
- advanced non small cell lung cancer
- squamous cell carcinoma
- end stage renal disease
- small cell lung cancer
- chronic kidney disease
- ejection fraction
- radical prostatectomy
- newly diagnosed
- palliative care
- prognostic factors
- type diabetes
- patient reported outcomes
- radiation therapy
- adipose tissue
- skeletal muscle
- single molecule
- benign prostatic hyperplasia
- structural basis